EUVIMEDEUVIMED entdecken
Open Access

Therapeutic inhibition of ATR in differentiated thyroid cancer

Shu-Fu Lin iD, Yi-Yin Lee, Ming-Hsien Wu, Yu-Ling Lu, Chun-Nan Yeh, Wei-Yi Chen, Ting-Chao Chou, Richard J Wong

Endocrine-Related Cancer · 2023

DOI: 10.1530/erc-23-0142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2023. Verfasst von Shu-Fu Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ataxia telangiectasia and Rad3-related protein (ATR) is a critical component of the DNA damage response and a potential target in the treatment of cancers. An ATR inhibitor, BAY 1895344, was evaluated for its use in differentiated thyroid cancer (DTC) therapy. BAY 1895344 inhibited cell viability in four DTC cell lines (TPC1, K1, FTC-133, and FTC-238) in a dose-dependent manner. BAY 1895344 treatment arrested DTC cells in the G2/M phase, increased caspase-3 activity, and caused apoptosis. BAY 1895344 in combination with either sorafenib or lenvatinib showed mainly synergistic effects in four DTC cell lines. The combination of BAY 1895344 with dabrafenib plus trametinib revealed synergistic effects in K1 cells that harbor BRAF V600E. BAY 1895344 monotherapy retarded the growth of K1 and FTC-133 tumors in xenograft models. The combinations of BAY 1895344 plus lenvatinib and BAY 1895344 with dabrafenib plus trametinib were more effective than any single therapy in a K1 xenograft model. No appreciable toxicity appeared in animals treated with either a single therapy or a combination treatment. Our findings provide the rationale for the development of clinical trials of BAY 1895344 in the treatment of DTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsAdenocarcinomaAnimalsHumansPhenylurea CompoundsSorafenibAtaxia Telangiectasia Mutated ProteinsQuinolinesImidazolesOximes

Stichwörter der Autor:innen

ATRBAY 1895344combination therapydabrafenibdifferentiated thyroid cancerlenvatinibsorafenibtrametinib

Substanzen

Phenylurea CompoundsSorafenibAtaxia Telangiectasia Mutated ProteinslenvatinibQuinolinesdabrafenibImidazolesOximesATR protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan.
  • College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Department of Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
  • Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Laboratory of Preclinical Pharmacology Core, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Shu-Fu Lin

Förderung

  • NCI NIH HHS

Zitieren

APA

Lin, S. F., Lee, Y. Y., Wu, M. H., Lu, Y. L., Yeh, C. N., Chen, W. Y., Chou, T. C., & Wong, R. J. (2023). Therapeutic inhibition of ATR in differentiated thyroid cancer. Endocrine-Related Cancer. https://doi.org/10.1530/erc-23-0142

Vancouver

Lin SF, Lee YY, Wu MH, Lu YL, Yeh CN, Chen WY, et al. Therapeutic inhibition of ATR in differentiated thyroid cancer. Endocrine-Related Cancer. 2023. doi:10.1530/erc-23-0142

BibTeX
@article{Lin2023,
  author = {Lin, Shu-Fu and Lee, Yi-Yin and Wu, Ming-Hsien and Lu, Yu-Ling and Yeh, Chun-Nan and Chen, Wei-Yi and Chou, Ting-Chao and Wong, Richard J},
  title = {Therapeutic inhibition of ATR in differentiated thyroid cancer},
  journal = {Endocrine-Related Cancer},
  year = {2023},
  doi = {10.1530/erc-23-0142}
}
Kostenlos starten →